Automation of aging research compound screening reaches unprecedented scale

The capacity to screen massive compound libraries for genuine geroprotectors has reached a new inflection point. An international consortium developed an integrated high-throughput platform evaluating over 400 small molecules in yeast, nematodes, fruit flies, killifish, and mice, deploying miniaturized automated assays with machine learning-based image analysis and no-transfer mortality detection. Across five evolutionarily distant models, only a subset of compounds achieved consistent lifespan extension, underscoring the persistent gap between model-specific findings and truly conserved pharmacological regulators of longevity. Nevertheless, six candidates—baicalein, doxycycline, forskolin, metformin, resveratrol, and rifampicin—demonstrated significant positive effects across multiple species, mapping a tractable space of reproducible interventions. For the longevity-conscious reader, the lesson is unambiguous: automation and cross-species validation are now indispensable tools for distinguishing laboratory noise from genuine progress in the pharmacology of aging.